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Background: Adipose-derived mesenchymal stem cell (ADMSC) therapy in regenerative medicine is a rapidly
growing area of research and is currently also being used to treat osteoarthritis (OA). Force platform analysis has
been consistently used to verify the efficacy of different therapeutic strategies for the treatment of OA in dogs, but
never with AD-MSC.
The aim of this study was to use a force platform to measure the efficacy of intraarticular ADMSC administration for
limb function improvement in dogs with severe OA.
Results: Eight lame dogs with severe hip OA and a control group of 5 sound dogs were used for this study. Results
were statistically analyzed to detect a significant increase in peak vertical force (PVF) and vertical impulse (VI) in
treated dogs. Mean values of PVF and VI were significantly improved after treatment of the OA groups, reaching
53.02% and 14.84% of body weight, respectively, at day 180, compared with only 43.56% and 12.16% at day 0.
Conclusion: This study objectively demonstrated that intraarticular ADMSC therapy resulted in reduced lameness
due to OA.
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Osteoarthritis (OA) is a common disorder in veterinary
medicine, and clinicians are increasingly encountering
this condition [1,2]. However, restoration of the diseased
articular cartilage in patients with OA is still a challenge
for researchers and clinicians. Currently, several experi-
mental strategies have investigated whether mesenchy-
mal stem cells (MSCs), instead of chondrocytes, can be
used for the regeneration and maintenance of articular
cartilage in OA [3].
Autologous stem cell therapy in the field of regenera-
tive veterinary medicine involves harvesting tissue,such
as fat or bone marrow [4], from the patient, isolating the* Correspondence: jvilar@dpat.ulpgc.es
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reproduction in any medium, provided the orstem and regenerative cells, and administering the cells
back to the patient [5]. The field of adipose-derived MSC
therapy (ADMSC) is a rapidly growing area of research,
and it has been shown that stem cells have an affinity
for damaged joint tissue; recent in vivo studies have con-
firmed that stem cells have the ability to localize and
participate in the repair of damaged joint structures, in-
cluding cruciate ligaments, menisci, and cartilage lesions
[6]. For these reasons, stem cell therapy is now being
used to treat OA.
Previous studies evaluating OA therapy in dogs sug-
gest that non-steroidal anti-inflammatory drugs do not
often provide complete pain relief [7], perhaps because
they rely on a single target receptor or pathway for their
action. In contrast to drug therapy, cellular therapies
such as ADMSCs play a trophic function by recruiting
endogenous cells to the injured site. Studies and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Evolution of PVF in lame group dogs after treatment
at the 6-month follow-up period.
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gous ADMSC therapy is of clinical benefit in horses and
dogs with orthopedic conditions [8-12].
Recent investigations have shown that growth factors
contained in platelet-rich plasma (PRGF) act as vehicles
and even potentiators of the effect of MSCs [13,14]. The
purpose of this study was to use force platform kinetic
analysis to evaluate the effect of a single intraarticular
injection of ADMSCs in 8 dogs with OA of hip joints by
measuring peak vertical force (PVF) and vertical impulse
(VI), which represent maximal weight bearing and distri-
bution of forces through time, respectively.
Results
The body weight of enrolled dogs ranged from 41 to 53
kg (mean ± SD = 47.1 ± 3.7 kg), and ages were 4 to 8
years (5.2± 1.7 years). The mean (± SD) value for walk-
ing velocity of both sound (control) and diseased groups
of dogs was 1.6 ± 0.5 m/s. No significant difference in
walking velocity existed between dogs (P= 0.06). PVF
and VI mean values are summarized in Table 1.
Analysis of PVF
More-lame limbs analysis showed that differences in %
PVF between D0 and D30 were significant (p-value<
0.001). Between the other periods, differences were of no
significance (p-value > 0.349).
Compared with the control group, % PVF at D0 is sig-
nificantly less (p-value< 0.001). In comparison, beyond this
time differences became non significant (p-value >0.499).
Less-lame limbs analysis showed non significant differ-
ences till D30 (p value = 0.058); beyond D90, differences
were significant (p-value<0.001).
Compared with control group, % PVF at D0 is signifi-
cantly greater at D0 (p-value < 0.001), D30 (p-value =0.03)
and D90 (p-value=0.015). At D180 this difference was not
significant (p-value =0.14) (Figure 1).Table 1 Mean and standard deviation of PVF and VI in %
dog weight (N/N and N.s/N, respectively) applied on the
diseased leg
Day 0 30 90 180
PVF ML 43.56 ± 0.73 49.21 ± 2.1 49.05 ± 1.51 53.2 ± 4.43
PVF LL 55.98 ± 0.62 53.96 ± 1.46 52.67 ± 1.91 51.53 ± 2.79
PVF S 47.40 ±1.43 47.74 ± 1.34 47.95 ±1.35 47.94 ± 1.65
VI ML 12.16 ± 0.72 13.75 ±1.17 13.71 ± 1.1 14.84 ± 1.29
VI LL 16.09 ± 1.01 15.51 ± 1.28 15.12 ± 1.45 14.83 ± 1.54
VI S 14.51 ± 0.47 14.62 ± 0.41 14.67 ± 0.42 14.67 ± 0.51
PVF ML: peak vertical force in the more-lame limbs. PVF LL: peak vertical force
in the less-lame limbs. VI ML: vertical impulse in the more-lame limbs VI LL:
vertical impulse in the less-lame limbs. PVF S: peak vertical force in the control
group. VI S: vertical impulse in the control group.
Data are shown for each day of observation.Analysis of VI
More-lame limbs analysis showed that differences in %
VI between D0 and D30 were significant (p-value<
0.001). With the other periods, differences were not sig-
nificant (p-value > 0.05).
Compared with the control group, % VI at D0 is signifi-
cantly less (p-val = 0.024). In comparison, beyond this
time differences became not significant (p-value > 0.84.
Less-lame limbs analysis showed no significant differ-
ences at any control period (p value > 0.462).
Compared with the control group, no significant dif-
ferences were also found (p-values > 0.876) (Figure 2).
Association between more and less-lame limbs
The fitted linear mixed model shows a negative association
between % PVF in less-lame limb and more-lame limbFigure 2 Evolution of VI in lame group dogs after treatment at
the 6-month follow-up period.
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tween VI in less and more -lame limb (β1=0, p-val=0.61).
The validity of the model fit was assessed by testing nor-
mality and homoscedasticity of the residuals. Both as-
sumptions could be accepted: the Shapiro-Wilk test for
normality and Levene’s test for homoscedasticity were not
significant (P = 0.67 and P = 0.995, respectively).
Discussion
In this trial, the effect of MSCs in lame OA dogs was
investigated and quantified by means of an objective
evaluation with a force platform. The ground reaction
forces-related aspects of the gait, such as the PVF and
VI, which represent maximal weight bearing and distri-
bution of forces through time, respectively, measured
the clinical impact of MSC treatment on the function of
the limb during the stance phase of walking.
The absence of a direct relationship between radio-
graphic evidence of OA and force platform findings is
well known; in any case, in our study, diseased dogs
were selected both on the basis of the presence or ab-
sence of radiographic evidence of severe OA (D-E de-
grees of hip dysplasia) and for evident lameness
objectively determined by platform gait analysis [15].
Voss et al. [16] and Evans et al. [17] reported that
force platform gait analysis at trot was much more sensi-
tive than at walk for low-grade hindlimb lameness, but
not for severe lameness. In our case, lameness of the OA
dogs group was evident by direct observation, even at
walk.
Although each dog had bilateral lameness, we believe
that confident data could only be obtained from the
more-lame limbs (lesser PVF), in order to limit a pos-
sible bias caused by inconsistent weight redistribution to
the less affected contra-lateral hindlimb. In fact, mean
values showed how initially less-lame limbs seemed to
be “better” than limbs from the control group.
We observed a substantial improvement both in PVF
and VI values through the period of evaluation, with an
indicative gaining of limb function. Evolution of VI
seems to be something controversial since some authors
suggest that recordings of improvement in VI may suffer
from a delay; their dogs tended to decrease their stance
time in comparison with baseline values after non-
steroidal anti-inflammatory drug treatment because they
were able to improve their performance. However, other
authors affirm that stance time did not change or increase
when limb function improved [18-20]. In our study we ob-
served independent evolution of both PVF and VI values,
we hypothesize that this fact occurs because PVF only de-
pends on the force exerted by the limbs, whilst VI reflects
the evolution of the force during the whole support phase.
For this reason VI could vary when one or both variables
change (force and support time).In 1999 Budsberg et al. compared the efficacy of a
treatment(Etodolac) with a placebo control group and
demonstrated a decrease in lameness in the treatment
group using force platform analysis. In contrast, the de-
gree of lameness in the dogs receiving the placebo dete-
riorated during the study period, making the control
group unable to provide fixed reference data [21]. Based
on their results, we designed the experimental study
using a control group of sound dogs that were able to
provide fixed reference data.
Different adipose tissue donor sites have been found in
revised literature: retroperitoneal adipose tissue [22], lat-
eral thoracic area [23], gluteous fat [24] or inguinal
region [5,25]. We preferred this location to others be-
cause it is easier to access, abundant quantities of fat,
absence of surgical complications and production of a
non visible scar.
Regarding cartilage healing, Murphy et al. published in
2003 that the use of MSCs deposited in a fibrin matrix
would be useful [26]. However, although a recent equine
study demonstrated early benefit, no significant differ-
ences were noted when MSCs plus fibrin were compared
to fibrin alone at 8 months [27]. Based on that work, it
is likely that modulation of the matrix or cells will need
to be accomplished to observe long-term benefit of
MSCs for cartilage repair. Treatment timing in relation
to the degree of pathology could also be a factor contri-
buting to the insignificant results of the equine study.
Specifically, because MSCs appear to have a tropism for
damaged cells, including fibrillated articular cartilage, it
may be that at day 14 (day of treatment) the degree of
fibrillation was not enough to allow an MSC treatment
effect. However, more observation and studies on cases
with more advanced fibrillation need to be conducted to
answer this question. Following those results, our study
was designed using animals with severe and chronic OA,
where chondral degeneration and fibrillation were
clearly present. These criteria could explain why our dis-
eased dogs showed highly significant improvements in
limb function.
Moreover, our study supports previously published data
demonstrating that a single intraarticular administration
of ADMSCs associated to PRGF-Endoret decreases pain
and lameness in dogs with OA over at least a 6-month
period [12], although our study was conducted in a
different joint and our results were supported by objective
kinetic data.
A follow up of six months could be considered as a
standard for testing the evolution of a medical or surgi-
cal treatment, although our dogs always seemed to
improve during the first month after treatment. Beyond
this time lapse not significant changes were statistically
detected. Recent clinical evaluation of this same treat-
ment in a much larger group of animals with
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that apparently improvement could be prolonged for
about 10 month (JM Carrillo, unpublished observations)
when dogs seemed to start to worsen. This is a fact that
could be contrasted with a biomechanic evaluation of a
homogeneous larger group of hip OA dogs of the same
breed and should encourage researchers to objectively
determine when a new cycle of treatment should be use-
ful to stop a relapse.
Regarding statistical analysis, more complex models
could have been considered but we chose this one be-
cause it offers an adequate compromise between com-
plexity and ability to represent the relationships between
the considered variables [28,29].
Conclusion
Force platform analysis demonstrated quantitatively that
ADMSC+ PRGF-Endoret therapy shows significant po-
tential for clinical use in the treatment of lameness asso-
ciated with OA.
Although this study was limited to a small number of
dogs with severe OA, MSC therapy was found to be an
appropriate treatment for hip joints, in terms of its effi-
cacy in objectively improving the dogs’ gait and ability to
live a more normal life, and the absence of side effects.
In the future, ADMSCs could also become a promising
therapeutic strategy in human OA.
Methods
The research protocol was revised and authorized by the
Ethical Committee of Animal Welfare (CEBA) of the
University of Las Palmas de Gran Canaria (Spain) with
reference code: 001/2010 CEBAULPGC.
Animals
Eight adult client-owned Canarian Presa dogs (5 males,
3 females) with lameness and pain attributed to OA
associated with hip dysplasia were included in the study.
The dogs were affected by chronic OA and had not
received any kind of medications (e.g., non-steroidal
anti-inflammatory drugs, analgesics), nutraceuticals
(e.g., glucosamine or chondroitin, vitamin E, omega-3
fish oil), or adjunctive therapies (e.g., acupuncture) for at
least 2 months. A control group consisted of 5 sound and
healthy dogs of the same breed.
None of the dogs were forced to perform physical ac-
tivity. Dog owners were informed and granted a signed
consent for the whole procedure.
Radiographs confirmed the presence of OA compatible
with D and E degrees of hip dysplasia as defined by the
Fédération Cynologique Internationale (World Canine
Organization). D- degree dysplasic dogs showed obvious
deviation from the normal with evidence of a shallow ace-
tabulum, flattened femoral head, poor joint congruency,and in some cases, subluxation with marked changes of
the femoral head and neck. E-degree dysplasic dogs
showed complete dislocation of the hip and severe flatten-
ing of the acetabulum and femoral head [30]. Additional
radiographs of knee and elbow joints were taken after
physical and orthopedic examinations were performed to
ensure that hip OA was the main reason for the observed
clinical signs and that general health was otherwise
normal.
Extraction and culture-inoculation of ADMSCs
and PRGF-Endoret
Stem cell extraction and inoculation phases were
performed under general anesthesia (sevofluorane). Adi-
pose tissue (20 g) was collected from the inguinal region
through a small surgical incision and then included in a
sterile bottle with culture medium for the cellular main-
tenance. Additionally, 120 ml of blood was extracted in
sterilized conditions and deposited in 8 ml serum tubes.
The adipose tissue and the blood tubes were sent to
Fat-Stem Laboratories (Buggenhout, Belgium) where
they were processed using the patent protocol of Dog
Stem® (Fat-Stem). The number of messenchymal stem
cells was over 30 million, shown in the laboratory
certificate for the quality of the cells and were sent in
two 2 ml tubes with 15 million per tube.
Once the AMSC were received they were infiltrated
with the PRGF-Endoret that was prepared in that mo-
ment following a patented method [31]: 20 ml of blood
were aseptically collected in four 4.5 ml citrate tubes,
then centrifugated during 8 minutes at 460 G. Before
the infiltration the PRGF was activated with 5% of its
volume with 10% calcium chloride.
Subsequently, PRGF-Endoret was associated to ADMSC.
The resultant 4 ml solution was injected aseptically into
the hip joints through conventional arthrocentesis sites.
The needle was introduced just cranioproximal to the
trochanter major, aimed slightly ventrally and caudally.
The appearance of joint fluid confirmed proper needle
placement [32].
Gait analysis
Gait analysis was performed using a single platform
mounted in the center of, and level with, a 7-m runway
covered by a rubber mat. The mat weight was discarded
setting to “0 force” with the tare button after the plat-
form was covered. Dogs were leash guided at walk over
the force platform by the same handler. Walk velocity was
measured by use of a motion sensor (Pasco, California,
USA) positioned 1 m from the platform.
Five valid trials, at a sampling frequency of 250 Hz,
were obtained for each dog. A trial was considered valid
when the limb fully contacted the force platform, and
with the dog walking next to the handler without pulling
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tracted during the measurement, if the limb struck the
edge of the force plate, or if any portion of the contralat-
eral paw hit the force plate. A member of the research
team (BC) evaluated the trial to confirm which limb
touched the center of the force platform.
The platform was interfaced with a dedicated com-
puter using DataStudio (Pasco, California, USA), soft-
ware specially designed for the acquisition, numerical
conversion, and storage of data. A team member (JMV)
recorded data from both affected limbs at day 0, 30,
90, and 180 post-treatment; the obtained PVF and VI
values were normalized relative to body weight (%) to
characterize the possible improvement of lameness
during treatment with MSCs.
Statistical analysis
Parameters in this model were estimated by using the
package nlme in the R statistical software [33]. Data
were analyzed by a different, blinded researcher (AS)
who did not perform acquisition of data. For the analysis
of these data, a linear mixed effects model for a blocked
design with repeated measures was considered [28,29].
The experimental factor (time) and the status (lame-
sound) of the dog were considered as fixed effects fac-
tors, while the blocking factor (dog) was a random
effects factor. Because the dogs represent a random sam-
ple of the population of interest, any interaction terms
modeling differences between dogs in its response when
changing from different observation periods will also be
expressed as random effects. Thus, the model we con-
sider is of the form:
yijkl ¼ βi þ γ j þ βγð Þij þ bjkj þ bijkj þ ijkjl
with i=0,1,3,6 (months), j=0 (sound), 1 (lame), k0=1,…,8,
k1=1,…,5, l=1,…,5. In this model, βi represents the effect
of time, γj the effect of the dog being sound or lame and
(βγ)ij the interaction between these factors. The term
bjkrepresent the random effects of the dogs, and the bijk
represents the random interaction terms between dogs
and time, being:








; ijkjl ∼ N 0; σ
2
 
Significance of the differences in PVF and VI between
periods of observation were tested by means of analysis
of variance of these models. Following this analysis,
post-hoc comparisons between fixed effects were
performed using Tukey’s procedure. For assessing the
validity of the model, the Shapiro-Wilk test was applied
for testing normality of the residuals.
For assessing the relationships between supporting
force in the more-lame and the less-lame limbs and also
between vertical impulses in the two limbs, a regressionmodel with random effects of dog on slope and intercept
was used:
yij ¼ β0 þ b0 þ β1 þ b1ð Þxi þ ij
with:
b0 ∼ N 0; σ20
 
; b1 ∼ N 0; σ21
 
; ij ∼ N 0; σ2
 
Here yij represents the value (PVF or VI) in the less-
lame limb and xij the value in the more-lame limb.
Significance level was set at P ≤ 0.05 in all tests.
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